- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$253 MnMarket Estimate, 2026
$279.57 MnMarket Forecast, 2034
$621 MnCAGR, 2026–2034
10.5%Executive Summary: North America Breast Biopsy Market
- Market Scope: Regional analysis of the North American breast biopsy sector, detailing valuation metrics, product types, guidance systems, country-level growth, core drivers, and major industry players.
- Market Valuation: Valued at USD 253.00 million in 2025, estimated to reach USD 279.57 million in 2026, and projected to scale up to USD 621.00 million by 2034, growing at a robust CAGR of 10.50% from 2026 to 2034.
- Primary Growth Drivers: Rising breast cancer incidence among aging demographics, growing preference for minimally invasive procedures, and robust government screening initiatives.
Key Market Segment Metrics
| Category | Leading Sub-Segment (2025 Base) | Fastest-Growing Sub-Segment |
|---|---|---|
| By Type | Needle Breast Biopsy (dominant volume share due to minimal invasiveness and quicker recovery) | Minimally Invasive Needle-Based Systems |
| By Product | Biopsy Needles & Guidance Systems (capturing substantial revenue share backed by frequent clinical utilization) | Advanced Localization Wires & Tables |
| By Guidance | Mammography-Guided & Ultrasound-Guided Biopsy | MRI-Guided Breast Biopsy Systems |
| By Country | The United States (holding the largest share of the North American market driven by early adoption of advanced medical technologies) | Canada & Mexico (growing via rising screening adoption) |
Major Market Players & Industry Landscape
Market Structure: Highly competitive oncology diagnostics landscape characterized by advanced vacuum-assisted devices, continuous technological innovations, and organized screening programs.
Key Companies: Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule Medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.
North America Breast Biopsy Market Size
The North America breast biopsy market was valued at USD 253 million in 2025, is estimated to reach USD 279.57 million in 2026, and is projected to reach USD 621 million by 2034, growing at a CAGR of 10.50% from 2026 to 2034.
MARKET DRIVERS
Rising Cancer Cases and Technological Advancements Drive Market Growth
The rising demand for minimally invasive treatments, an increase in cancer cases, and government programs for early cancer diagnosis are the key drivers driving the market's growth in the North American region. In addition, the rise in the market can be attributed to an increase in the occurrences of breast cancer, which is most often observed in females over 35 years of age following menopause, as well as increasing awareness of breast cancer screening programs. Various product enhancements, which are constantly being introduced into the market, are also likely to influence this industry throughout the forecast period positively.
The rising frequency of the disease and increased awareness campaigns are driving up the number of screened and diagnosed people. Healthcare workers commonly utilize mammograms and ultrasounds to detect breast cancer. Several types of technologies and products, including biopsy guiding systems, needle-based biopsy guns, and vacuum-assisted devices, are expected to expand rapidly during the forecast period. New growth opportunities are expected to arise in the near future as new technologies emerge and the use of mammography-guided stereotactic biopsy rises. Various businesses are undertaking clinical studies to demonstrate the efficacy and efficiency of liquid biopsy in cancer; the encouraging results are likely to open up new opportunities for market participants in this region. The demand for biopsy operations is likely to rise in the future years as people become more aware of various cancers.
MARKET RESTRAINTS
Regulatory Hurdles and High Costs Likely to Restrict Market Expansion
In the next few years, strict regulatory approval procedures, lack of specific regulatory concerns, infection risks connected with breast biopsy procedures, and uncertain reimbursement policies and product recalls are likely to limit the market's growth. In addition, high procedure costs and demand skewed towards a specific gender and middle age to senior age group are obstacles in this industry, excluding a large portion of the population.
The dangers associated with the procedures are expected to have a negative impact on the Breast Biopsy Device Market. The invasiveness of the process determines the level of danger. Surgical core treatments may be more precise and successful, but they come with major risks. However, qualified surgeons to perform minimally invasive biopsy techniques are in limited supply.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Type, Product, Guidance, and Region. |
| Various Analyses Covered | Global, Regional and Country-Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Countries Covered | United States, Canada, Mexico, Rest of North America |
| Market Leaders Profiled | Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL. |
REGIONAL ANALYSIS
Geographically, due to the early adoption of new medical technologies and the ongoing expansion of cancer diagnostics companies, North America is expected to have the largest breast biopsy market share. North America accounts for the largest share with increased awareness obtained via cancer screening programs and other supporting government measures. The region's largest economies, including the United States and Canada, are the primary revenue providers to the regional market value. In addition, the region has a potential medical tourism market, which helps to support the region's dominant market value. The early adoption of improved breast biopsy technologies, continuous technical developments, rising breast cancer incidence, and the fast-increasing elderly population that is more prone to developing breast cancer are all factors that contribute to the region's significant proportion.
KEY MARKET PLAYERS
Companies playing a dominant role in the North America Breast Biopsy Market profiled in this report are Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.
MARKET SEGMENTATION
This research report on the North American Breast Biopsy Market has been segmented and sub-segmented into the following categories.
By Type
- Open Surgical Breast Biopsy
- Needle Breast Biopsy
By Product
- Biopsy Tables
- Localization Wires
- Biopsy Needles
- Guidance Systems
- Others
By Guidance
- MRI-Guided Breast Biopsy
- Mammography-Guided Stereotactic Breast Biopsy
- Ultrasound-Guided Breast Biopsy
- Other Techniques
By Country
- The United States
- Canada
- Rest of North America
